| Literature DB >> 34874509 |
Christophe Beyls1,2, Alexis Hermida3, Yohann Bohbot4, Nicolas Martin5, Christophe Viart5, Solenne Boisgard5, Camille Daumin5, Pierre Huette5, Hervé Dupont5, Osama Abou-Arab5, Yazine Mahjoub5.
Abstract
BACKGROUND: Atrial fibrillation (AF) is the most documented arrhythmia in COVID-19 pneumonia. Left atrial (LA) strain (LAS) analysis, a marker of LA contractility, have been associated with the development of AF in several clinical situations. We aimed to assess the diagnostic ability of LA strain parameters to predict AF in patients with severe hypoxemic COVID-19 pneumonia. We conducted a prospective single center study in Amiens University Hospital intensive care unit (ICU) (France). Adult patients with severe or critical COVID-19 pneumonia according to the World Health Organization definition and in sinus rhythm were included. Transthoracic echocardiography was performed within 48 h of ICU admission. LA strain analysis was performed by an automated software. The following LA strain parameters were recorded: LA strain during reservoir phase (LASr), LA strain during conduit phase (LAScd) and LA strain during contraction phase (LASct). The primary endpoint was the occurrence of AF during ICU stay.Entities:
Keywords: Atrial fibrillation; COVID-19; Intensive care unit; Left atrial strain; Pneumonia
Year: 2021 PMID: 34874509 PMCID: PMC8649321 DOI: 10.1186/s13613-021-00955-w
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Fig. 1Measurement of LAS parameters with an automated software. LA strain values were automatically measured during the different LA phases: LASr measured as the first peak positive deflection, LAScd measured as the difference between LASr and LASct values, LASct measured as the beginning of the P wave contraction. LAS: left atrial strain. LASr: left atrial strain reservoir phase. LAScd: left atrial strain conduit phase. LASct: left atrial strain contraction phase
General characteristic data of the study population
| Variables | No AF | AF | P value |
|---|---|---|---|
| Age (years) | 65 [59–70] | 73 [65–76] |
|
| BMI (kg.m−2) | 31.5 [24.9–40.7] | 29.3 [26.2–32.8] | 0.8 |
| SAPS II score during TTE | 32 [21–49] | 58 [43–62] |
|
| Male gender | 40 (65) | 14 (88) | 0.12 |
| Medical history | |||
| No history | 8 (13) | 3 (19) | 0.68 |
| Hypertension | 31 (50) | 12 (75) | 0.09 |
| Diabetes | 13 (21) | 6 (38) | 0.19 |
| Dyslipidemia | 19 (31) | 4 (25) | 0.76 |
| Smoking (former or active) | 20 (33) | 4 (25) | 0.76 |
| Chronic renal disease | 5 (8) | 2 (12) | 0.62 |
| COPD/asthma | 11 (18) | 2 (13) | 1 |
| Coronary or peripheral artery disease | 15 (24) | 5 (32) | 0.53 |
| Obstructive sleep apnea | 5 (8) | 1 (6) | 1 |
| Chronic treatment | |||
| Statine | 19 (31) | 7 (44) | 0.38 |
| Beta blocker | 17 (28) | 6 (38) | 0.54 |
| ACE inhibitor | 11 (18) | 5 (32) | 0.30 |
| ARBs | 14 (23) | 3 (18) | 1 |
| Diuretic | 9 (15) | 4 (25) | 0.45 |
| Aspirin | 14 (23) | 6 (38) | 0.33 |
| Metformin | 9 (15) | 4 (25) | 0.45 |
| Time to first symptom to ICU admission (days) | 8 [5–11] | 8 [4–14] | 0.56 |
| COVID 19 specific treatment (n = 67/89) | |||
| Dexamethasone | 49 (81) | 11 (74) | 0.70 |
| Remdesevir | 3 (5) | 0 | 1 |
| Tocillizumab | 1 (2) | 0 | 1 |
| Atrial fibrillation | |||
| Previous paroxysmal AF | 6 (10) | 2 (12) | 0.61 |
| Occurrence of AF, (days) | – | 7 [2–11] | – |
| CHA2DS2-VASc | 2 [1–3] | 3 [1–4] | 0.20 |
| Outcome | |||
| Arterial thromboembolic events | 0 | 1 (6)* | 0.21 |
| Length under MV, | 17 [10–24] | 28 [16–44] |
|
| Mortality at 30-days | 14 (22) | 7 (43) | 0.11 |
| ICU discharge, | 61 (93) | 13 (82) | 0.06 |
| Length of stay in ICU, | 12 [5–21] | 25 [14–33] |
|
Bold indicates P < 0.05
Continuous variables are expressed as median [interquartile range] and categorical variables as number (percentage)
ACE angiotensin-converting enzyme, AF atrial fibrillation, ARBs angiotensin II receptor blockers, BMI body mass index, COPD chronic obstructive pulmonary disease, ICU intensive care unit, MV mechanical ventilation, SAP systolic arterial pressure, SAPS simplified acute physiology score, TTE transthoracic echocardiography
*ischemic stroke
Fig. 4C-statistic and receiver operating characteristics curve (ROC) of factors associated with the occurrence of AF. The ROC curve analyzed the discrimination ability of the model composed of LAScd and SOFA cv > 1 to predict AF. AF: atrial fibrillation; AUC: area under curve; CV: cardiovascular; ROC: receiver operating characteristic curve. SOFA: sequential organ failure assessment
Factors associated with occurrence of AF in pneumonia related to COVID-19 infection
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95%CI) |
| OR (95%CI) |
| |
| LAScd (for each 1% increase) | 1.27 [1.10–1.47] | 0.001 | 1.24 [1.04–1.48] |
|
| LASr (for each 1% increase) | 0.89 [0.83–0.95] | 0.002 | NS | |
| SOFA cv > 1 | 6.4 [1.96–20.9] | 0.002 | 5.56 [1.41–22.11] |
|
| PEEP | 0.86 [0.68–1.09] | 0.86 | NR | – |
Bold indicates P < 0.05
The multivariable model showed a good calibration as assessed by the Hosmer and Lemeshow goodness of fit test [p = 0.98] and a fair discrimination as assessed by the receiver operating characteristics curve [area under the curve (AUC) 0.89; 95% CI 0.80–0.97; p < 0.001] (Fig. 4)
CI confidence interval, CV cardiovascular, LAScd left atrial strain during conduit phase, SOFA sequential organ failure assessment, PEEP positive end-expiratory pressure. NR not retained in the final model, NS not significant in the final model
Fig. 5Cumulative risk of AF according to LAScd. AF: atrial fibrillation; LAScd: left atrial strain conduit phase
Hemodynamics parameters and biological investigations during TTE exam
| Hemodynamic | |||
| HR, | 82 [71–90] | 78 [59–103] | 0.66 |
| SAP, | 128 [115–138] | 120 [110–131] | 0.11 |
| DAP, | 65 [59–73] | 62 [53–71] | 0.27 |
| MAP, | 86 [76–94] | 85 [71–91] | 0.46 |
| SpO2, | 93 [91–96] | 93 [91–96] | 0.74 |
| T, | 37.6 [36.7–38.3] | 36.8 [36.4–37.7] | 0.07 |
| SOFA score during TTE | 3 [2–5] | 5 [3–10] | 0.002 |
| SOFA cardiovascular score during TTE | 0 [0–1] | 4 [1–4] | 0.0001 |
| Critical group (n = 25) | |||
| Norepinephrine use, | 14 (22) | 11 (69) | |
|
| 0.26 [0.12–0.96] | 0.15 [0.12–0.28] | 0.56 |
| Mechanical ventilation, | 25 (41) | 13 (81) |
|
|
| 10 [7–12] | 11 [9–14] | 0.73 |
| PaO2, | 79 [65–98] | 87 [68–120] | 0.96 |
| Biological investigations | |||
| WBC, | 9000 [6100–12900] | 7300 [5850–13525] | 0.47 |
| Lymphocyte count, | 700 [400–1250] | 800 [300–1100] | 0.84 |
| Hemoglobin, | 12.6 [11.1–13.4] | 12.0 [11.4–13.6] | 0.90 |
| C reactive protein, | 132 [97–220] | 152 [144–195] | 0.52 |
| Creatinin, umol l−1 | 71 [58–90] | 82 [56–154] | 0.23 |
| Troponine Tc HS, | 18 [6–42] | 48.5 [3.25–148] | 0.48 |
| BNP, | 66 [42–123] | 119 [40–185] | 0.42 |
Bold indicates P < 0.05
Continuous variables are expressed as median [interquartile range]
BNP brain natriuretic peptide, COPD chronic obstructive pulmonary disease, DAP diastolic arterial pressure, HR heart rate, MAP mean arterial pressure, PEEP positive end-expiratory pressure, SAP systolic arterial pressure, SOFA sequential organ failure assessment, Sp0 pulse saturation of oxygen, TTE transthoracic echocardiography, WBC white blood cell
Echocardiographic data
| Overall population ( | No AF ( | AF ( | |
|---|---|---|---|
| LV systolic parameters | |||
| LVEF (%) | 61 [51–69] | 66 [53–70] | 0.37 |
| LV end diastolic volume (ml) | 109 [74–129] | 109 [90–156] | 0.50 |
| LV end systolic volume (ml) | 43 [26–58] | 38 [24–65] | 0.85 |
| Stroke volume index (ml/m2) | 33 [26–39] | 27 [24–35] | 0.12 |
| Cardiac index (l/min/m2) | 2.49 [1.98–3.23] | 2.15 [1.78–3.01] | 0.24 |
| LV diastolic functional parameters | |||
| E wave (cm s−1) | 84 [69–92] | 77 [65–98] | 0.60 |
| A wave (cm s−1) | 83 [68–105] | 74 [61–100] | 0.63 |
| E/A ratio | 0.9 [0.74–1.2] | 0.8 [0.7–1.2] | 0.74 |
| Lateral E/e’ | 8.5 [6.3–10.4] | 9.7 [7.4–12.0] | 0.24 |
| E wave deceleration time (ms) | 250 [180–309] | 254[190–304] | 0.93 |
| LA volume (ml) | 49 [39–58] | 56 [32–67] | 0.52 |
| LA volume index (ml/m2) | 23 [18–27] | 28 [16–38] | 0.19 |
| RV Parameters | |||
| RV basal dimension (mm) | 46 [40–51] | 43 [41–50] | 0.72 |
| RV mid-cavity dimension (mm) | 34 [29.40] | 32 [26–39] | 0.38 |
| RV longitudinal dimension (mm) | 77 [71–82] | 74 [71–78] | 0.42 |
| RV EDA (cm2) | 20 [15–25] | 18 [16–21] | 0.37 |
| RV ESA (cm2) | 11 [7–15] | 9 [8–11] | 0.18 |
| RA volume indexed to BSA (ml/m2) | 21 [14–25] | 19 [15–25] | 0.95 |
| RV systolic function parameters | |||
| TAPSE (mm) | 24.2 [21.0–28] | 21.5 [18.2–24.1] | 0.6 |
| RV- S’ (cm/s-1) | 16.0 [13.4–19.4] | 18.0 [16.3–20.0] | 0.43 |
| RV FAC (%) | 47 [38–53] | 49 [46–53] | 0.23 |
| Pericardial effusion (> 10 mm) | 3 (5) | 2 (12) | 0.26 |
| Valvular heart disease | 2 (3)† | 1 (6)* | 0.10 |
| LA strain parameters | |||
| LASr (%) | 30.5 [23.8–36.2] | 20.2 [12.3–27.3] |
|
| LAScd (%) | − 17.2 [(− 5.0)–(− 10.2)] | − 8.1 [(− 6.3)–(− 10.9)] |
|
| LASct (%) | − 13.3 [(− 7.7)–(− 16.9)] | − 9.7 [(− 5.2)–(− 16.1)] | 0.31 |
Bold indicates P < 0.05
CO cardiac output, EDA end diastolic area, ESA end systolic area, FAC fractional area change, LA left atrial, LAScd left atrial strain during conduit phase, LASct left atrial strain during contraction phase, LASr left atrial strain during reservoir phase, LV left ventricle, LVEF left ventricular ejection fraction, RA right atrium, RV right ventricle, TAPSE tricuspid annular plane systolic excursion
*one moderate mitral regurgitation by prolapse
†one severe mitral regurgitation and one moderate aortic regurgitation
Reproducibility of LA strain analysis with an automated software
| LA strain parameters | ICC for inter-operator | 95% CI | ICC for intra-operator | 95% CI |
|---|---|---|---|---|
| LASr | 0.97 | 0.84–0.99 | 0.96 | 0.84–0.99 |
| LAScd | 0.86 | 0.52–0.96 | 0.94 | 0.78–0.98 |
| LASct | 0.89 | 0.74–0.98 | 0.90 | 0.61–0.97 |
CI confidence interval, ICC intraclass correlation coefficient, LA left atrial, LAScd left atrial strain during conduit phase, LASct left atrial strain during contraction phase, LASr left atrial strain during reservoir phase